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The effects of aspirin, flurbiprofen, and NO-donating acetylsalicylic acid
(NCX 4016) on mice models of endotoxic and septic shock
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Background/aim: Nitric oxide-donating nonsteroidal antiinflammatory drugs (NO-NSAIDs) are a promising new class of
antiinflammatory agents, which are obtained by adding NO-donating moieties to the existing conventional NSAID molecules. The aim
of this study was to investigate the effects of aspirin, flurbiprofen, and NO-donating acetylsalicylic acid (NCX 4016) on cecal ligation
and puncture (CLP) and endotoxin-induced septic shock (LPS) models in mice.
Materials and methods: Overall survival and spleen and liver weights were monitored in LPS and CLP models. Histopathological
examinations of liver and spleen were performed at the end of the experimental protocols.
Results: NCX 4016 was able to reverse the increased spleen weight in CLP-operated animals, whereas aspirin or flurbiprofen did not.
Similar to the results of the CLP model, none of the drugs modified the survival rates in the LPS model. Flurbiprofen in particular
produced significant histopathological damage in spleens and livers, which was less significant with aspirin. NCX 4016 did not cause
any liver damage.
Conclusion: NCX 4016 has the potential to be used in septic states, while special attention has to be paid to the effects of aspirin and
flurbiprofen on the liver and spleen.
Key words: Aspirin, flurbiprofen, NCX 4016, septic shock, cecal ligation and puncture, hepatotoxicity

1. Introduction
Sepsis is a severe systemic inflammatory response to an
infection. The causative agents are microorganisms or
their toxins, which spread from a local infection site. In the
majority of cases, the clinical outcome is worsened by the
development of multiple organ dysfunction, which leads
to an unrelenting state of acute circulatory failure, namely
septic shock (1). Septic shock remains one of the major
causes of death in intensive care units (2). Several pathways,
such as the arachidonic acid-cyclooxygenase pathway, have
been investigated to explain the pathophysiology of septic
shock (3). Among these, the maldistributon of blood flow
due to potent vasoactive mediators, such as nitric oxide
(NO) (4), has always retained its popularity.
NO-donating nonsteroidal antiinflammatory
drugs (NO-NSAIDs) constitute a promising class of new
antiinflammatory agents, which are obtained by adding
an NO-donating moiety to the existing conventional
NSAID molecules (5). They are reported to be active in
several experimental disease models, including sepsis (6–
* Correspondence: alperi@hacettepe.edu.tr
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9). The underlying mechanism of their beneficial effects
is suggested to be the reduction of gut injury due to the
release of NO (10). Since the inhibition of arachidonic acid
metabolites is known to be beneficial in endotoxemia (11)
and they have a pivotal role in the development of acute
respiratory distress syndrome in sepsis (12), NO-NSAIDs,
i.e. cyclooxygenase inhibitors that donate NO, appear to be
promising for the reduction of septic shock symptoms.
The role of NO in the pathophysiology of sepsis and
septic shock is controversial and currently under scrutiny
(13). The pro- and antiinflammatory effects of NO, as
well as its oxidant and antioxidant properties (14), have
been the source of interest and debate in sepsis research.
It is becoming clearer that NO may act both as friend
and foe in septic states (15). Since many deleterious
effects of endotoxins, such as hypotension (16) and
vascular hyporesponsiveness (17) to vasoconstrictors
(18) and vasodilators (19), could be explained by excess
NO production (20), the inhibition of NO to combat
septic shock was regarded as essential until recently. The
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usefulness of an NO-inhibiting drug for the treatment of
human toxic shock syndrome in an isolated case report (21)
has enhanced this belief. We showed the potential beneficial
effect of NO-induced local vasodilation, particularly in
the mesenteric circulation (22). Since splanchnic ischemia
increases mortality in septic shock (23), the restoration of
tissue perfusion by local vasodilation via NO may reduce
the bacterial translocation (24) and improve survival (25).
Therefore, we aimed to investigate the effects of
NCX 4016, an NO-donating derivative of aspirin, in
experimental models of septic and endotoxic shock, namely
cecal ligation and puncture (CLP)-septic and endotoxininduced endotoxic shock models, by comparing it with
aspirin and flurbiprofen. Although our main focus was on
overall survival, spleen weight, which reflects the severity
of septic state (22), and the histopathological alterations in
spleen and liver were also investigated.
2. Materials and methods
2.1. Animals
Swiss albino mice (35–45 g) were obtained from the
Laboratory of Animal Husbandry of the Department of
Pharmacology, Hacettepe University, and were housed
under environmentally controlled conditions at 21 ± 2
°C and 30%–70% relative humidity with a 12-h dark/light
illumination sequence (the lights were on between 0700 and
1900 hours), and ad libitum access to tap water (drinking
bottle) and standard pellet rodent chow (Korkutelim Yem
Sanayı, Antalya, Turkey). All animal experiments were
performed with strict adherence to European Community
guidelines and the Declarations of Helsinki and Tokyo,
and they were approved by the Institutional Experimental
Animal Care and Use Ethics Committee of Hacettepe
University before the commencement of any interventions
(Approval Number: 2004/55-4).
2.2. Mice model of septic shock induced by cecal ligation
and puncture
Polymicrobial sepsis was induced by adhering to the same
protocol of our previous study (26), which was based on
the detailed guidance of other publications (27,28). In
brief, mice were fasted overnight, but were allowed ad
libitum access to drinking water prior to the experiment.
The animals were then anesthetized with chloral hydrate
(400 mg/kg, i.p.) and placed on a heat-insulated cork
sheet-covered operating table. The animals were allowed
to breathe room air spontaneously. After the obtundation
of all responses to painful stimuli (pinching of the plantar
skin with tweezers), a 1-cm midline abdominal incision
was made. The cecum was then exposed, ligated by using
atraumatic 3-0 silk sutures to distal the ileocecal valve in
order to avoid any intestinal obstruction, and punctured
twice with a 22-gauge needle. The punctured cecum
was gently squeezed to expel a small amount of fecal

material, and the abdominal incision was then closed in
two layers by using atraumatic 4-0 silk sutures. Shamoperated animals underwent the same surgical procedure
except that the cecum was neither ligated nor punctured.
Immediately after the surgery all animals received a
subcutaneous injection of 1 mL of sterile saline (NaCl 0.9
%, w/v, dissolved in pyrogen-free distilled water).
After recovery from the surgery, the animals were
randomly allocated to different treatment groups (n = 14–
24) to receive twice-daily intraperitoneal injections of one
of the following: (i) conventional aspirin (acetylsalicylic
acid; 30 mg/kg per day), (ii) its nitric oxide-donating
derivative (NCX 4016; 50 mg/kg per day), or (iii)
flurbiprofen (6 mg/kg per day) until tissue harvesting
(maximum of 7 days, depending on the survival time of
an individual animal). These particular doses of the test
drugs were chosen on the basis of their activity in animals
obtained from published data. Likewise, the animals
in matching control groups received equal volumes of
either sterile saline or the vehicle mixture that was used to
dissolve the compounds (i.e. 50% (v/v) polyethylene glycol
400, 45% (v/v) nonpyrogenic sterile saline, and 5% (v/v)
dimethyl sulfoxide). NCX 4016, aspirin, and flurbiprofen
were dissolved daily in this vehicle, kept in dark containers
until the injections in order to protect them from lightinduced decomposition, and warmed to body temperature
(approximately 37 °C) before injections.
Survival rates were recorded at 12-h intervals for 168
h (7 days) after surgery, and all living animals were killed
humanely at the end of our observational period. Since our
previous study revealed a direct correlation between the
enlargement of the spleen and the presence and severity
of septic challenge, the spleens of all animals were isolated
and weighed as an indication of the success of the surgical
intervention.
In addition to spleens, livers were also isolated in some
randomly selected animals. The tissues were fixed in 4%
paraformaldehyde solution immediately after removal and
were then embedded in paraffin. The histopathological
sections were prepared and stained with hematoxylineosin staining. When the preparations exhibited fibrosis,
the corresponding adjacent sections were stained with
trichrome to confirm the presence of fibrotic changes.
The slides were examined under a conventional light
microscope (Zeiss Axioskop, Germany) by an appropriately
blinded pathologist.
2.3. Mice model of endotoxic shock induced by
lipopolysaccharide
Endotoxin derived from Escherichia coli (lipopolysaccharide
(LPS) O55:B5, 60 mg/kg, i.p.) or its vehicle saline (NaCl
0.9 %, w/v, dissolved in pyrogen-free distilled water) was
given by intraperitoneal injection to animals at a volume of
0.2 mL. This particular dose of endotoxin was chosen on
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the basis of our previous experience, which had revealed
a remarkable mortality rate within the first 24 h in mice
(22). After the injection of LPS, the animals were placed
in separate cages to recover from the intervention and
were randomly allocated to groups of 12–14 to receive
either aspirin or NCX 4016 treatments twice daily for
an observational period of 72 h (3 days). The control
animals received the same volume of the vehicles of LPS
(i.e. saline), aspirin, or NCX 4016 at the same time points.
Survival rates were then recorded for the following 72 h at
intervals of 1 h during the first 6 h, and at 12-h intervals
until the end of the observational period.
2.4. Drugs
Aspirin, flurbiprofen, and NCX 4016 were kindly provided
by NicOx S.A. (Sophia Antipolis, France). Chloral hydrate,
sodium chloride, dimethyl sulfoxide, hematoxylin (Merck,
USA), lipopolysaccharide O55:B5, polyethylene glycol 400,
eosin, trichrome (Sigma, USA), paraffin (Shandon, UK),
and formaldehyde (Carlo Erba, Italy) were purchased.
2.5. Statistical analysis
Fisher’s exact test for 2 × 2 tables was used to compare
the percent survival at selected time points (i.e. at the
end of 72-h or 168-h observation periods), while Cox
regression analysis was used to compare the trends of
the survival curves. The data related to the weight of the
spleen were analyzed with two-way analysis of variance
(ANOVA), while the rest of the pair-wise comparisons
were performed either with the Mann–Whitney U test
or Student’s t-test, where appropriate, depending on the
similarity of the standard deviations of the populations. P
< 0.05 was considered to be statistically significant, and the
actual values of P are indicated throughout the manuscript.

3. Results
3.1. Saline/vehicle controls in cecal ligation and puncture
model
The survival in saline-treated sham-operated animals was
92.9% (13 of 14) and it was 35.7% in the CLP group (5 of
14, P < 0.01) on day 7 (168 h) after the surgery. As shown
by the survival curves in Figure 1, the deaths occurred
consequently on a linear basis beginning at 24 h with
no apparent aggregation at any time point. There was no
significant effect of the vehicle, which was used to dissolve
test drugs in any of the parameters related to the survival.
The survival rate in the vehicle-treated CLP group was
45.8% (11 of 24) at 168 h, and this was not significantly
different than the corresponding value obtained from
saline-treated CLP animals (Figure 1).
In saline-treated animals, CLP significantly increased
spleen weight (g/kg body weight; sham-operated: 5.5 ±
0.6, n = 14 vs. CLP: 8.13 ± 0.8, n = 14; P = 0.0157). These
findings were further analyzed by using vehicle and CLP
as the variables in a two-way ANOVA test applied to all 4
groups, which revealed a significant interaction between
the aforementioned variables (P = 0.008) (Figure 2).
3.2. The effects of aspirin, flurbiprofen, and NCX 4016 on
the CLP model
As mentioned earlier, CLP resulted in a 45.8% (11 of 24)
survival rate at 168 h in vehicle-treated animals. When the
animals were treated with aspirin, the overall survival rate
was the same at 168 h. As such, the curves were almost
superimposable (Figure 3). Although NCX 4016 treatment
resulted in an apparently better overall survival at 168 h
(70.8%, 17 of 24), the difference from its corresponding
value failed to reach statistical significance (P = 0.1425).
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Figure 1. Survival rates obtained from mice that underwent sham or cecal ligation and
puncture (CLP) surgery and were then treated either with saline or vehicle, which was
used to dissolve drugs. Asterisk indicates significant difference (P < 0.05, two-tailed
value, Fisher’s exact test) from the corresponding value obtained from sham-operated
animals at 168 h. n = 14 in sham saline, sham vehicle, and CLP saline groups, n = 24 in
CLP vehicle group.
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Figure 2. The spleen weights (g/kg body weight, mean ± SEM) obtained from mice that
underwent sham or cecal ligation and puncture (CLP) surgery and were treated either
with saline or vehicle, which was used to dissolve drugs. Asterisk indicates significant
difference (P = 0.0157, two-tailed value, Mann–Whitney U test) from the corresponding
value indicated in the adjacent column. Two-way ANOVA, applied to the data obtained
from all 4 groups by using CLP and vehicle as the variables, indicated a significant (P =
0.008) interaction between them. n = 14 in sham saline, sham vehicle, and CLP saline
groups, n = 24 in CLP vehicle group.
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Figure 3. Survival rates obtained from mice that underwent cecal ligation and puncture
(CLP) surgery and were treated either with vehicle or conventional aspirin or its NOdonating derivative, NCX 4016. n = 24 in all groups.

Similarly, Cox regression analysis of the survival curves
did not indicate any significant difference (Figure 3).
The weights of spleen obtained from aspirin-treated
animals (8.23 ± 1.06 g/kg body weight, n = 24) were
significantly (P = 0.0282) greater than those of vehicletreated CLP animals (5.49 ± 0.57 g/kg body weight, n
= 24), while such an increase in spleen weight was not
observed in NCX 4016-treated animals (5.64 ± 0.71 g/kg
body weight, n = 24) (Figure 4).
In contrast to the results obtained by NCX 4016,
flurbiprofen failed to improve the survival rate (Figure
5). In addition, spleen weight was significantly (P =
0.0475) higher (8.23 ± 1.14 g/kg body weight, n = 14)

in flurbiprofen-treated animals when compared to the
vehicle-treated CLP animals (5.49 ± 0.57 g/kg body weight,
n = 24) (Figure 6).
3.3. The effects of aspirin and NCX 4016 on LPS-induced
model of septic shock
The survival rate was 100% in groups treated with vehicle
(n = 14), aspirin (n = 12), or NCX 4016 (n = 12), and it was
28.6 % in the LPS group (10 of 14, P = 0.0002 vs. controls).
Deaths were observed within 3 h of the LPS injection
(Figure 7). When the animals were treated either with
aspirin or NCX 4016 (n = 12 for each group) in addition to
LPS, mortality was 100% by hour 12. (Figure 7).
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Figure 4. The spleen weight (g/kg body weight, mean ± SEM) obtained from mice that
underwent cecal ligation and puncture (CLP) surgery and were also treated either with
vehicle, plain aspirin, or its NO-donating derivative, NCX 4016. Asterisk indicates
significant difference (P = 0.0282, two-tailed value, Student’s unpaired t-test) from the
corresponding value obtained from vehicle-treated animals. n = 24 in all groups.
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Figure 5. Survival rates obtained from mice that underwent cecal ligation and puncture
(CLP) surgery and were treated either with vehicle or flurbiprofen. n = 24 in vehicle and
flurbiprofen groups.
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Figure 6. Spleen weight (g/kg body weight, mean ± SEM) obtained from mice that
underwent cecal ligation and puncture (CLP) surgery and were treated either with
vehicle or flurbiprofen. Asterisk indicates significant difference (P < 0.05, two-tailed
value, Mann–Whitney U test) from the corresponding value obtained from vehicle
treated animals. n = 24 in vehicle and flurbiprofen groups.
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Figure 7. Survival rates obtained from mice that were given lipopolysaccharide (LPS) or
its vehicle, i.e. saline, which were also treated either with plain aspirin, its NO-donating
derivative, NCX 4016, or the vehicle. Single asterisk indicates significant difference
(P = 0.0002, two-tailed value, Mann–Whitney U-test) from the corresponding value
obtained from saline-treated animals. Double asterisk indicates significant difference
(P < 0.0001, two-tailed value, Mann–Whitney U test) from the corresponding value
obtained from vehicle-treated animals. n = 12–14 in each group.

3.4. The effects of drugs on spleen and liver histopathology
in CLP
CLP resulted in severe congestion (6 of 6 animals), minimal
fibrosis (2 of 6 animals), and capsulitis (1 of 6 animals)
in the spleens of randomly selected animals (n = 6). In
the aspirin-treated animals, both fibrosis and congestion
in the spleen were moderately less. However, NCX 4016
treatment caused milder histopathological findings than
in aspirin-treated animals. In contrast, flurbiprofen caused
remarkable congestion and severe fibrosis of the spleen in
all of the randomly selected specimens (n = 3) (Figure 8).
CLP resulted in mild focal “spotty” necrosis (5 of
6 randomly selected animals) and minimum degree
of congestion and capsulitis (2 of 6 randomly selected
animals) with no sign of fibrosis or any other degeneration
in liver. However, all of the test drugs caused severe focal
necrosis, moderate congestion, and capsulitis in the liver.
Severe fibrosis was detected in the livers of all randomly
selected flurbiprofen-treated animals, which was almost

completely absent in aspirin- or NCX 4016-treated animals
(Figures 9a and 9b).
4. Discussion
Despite the advances in research on the pathophysiological
mechanisms of sepsis and the refinements in the
management of septic patients, the high mortality and
morbidity rates in surgical intensive care units due to
sepsis, septic shock, and multiple organ failure have not
been significantly reduced in the past two decades (1).
Although an extensive amount of studies that demonstrated
significant beneficial effects of various procedures in
experimental animals exists, there is controversy about
their validity in terms of their relevance to human sepsis.
Most of the experimental models of endotoxic and
septic shock, such as infusion of bacterial endotoxin or
cecal ligation and puncture procedure, are rather acute
models of sepsis, and these models are used to improve or
to investigate short-term mortality and organ failure. The

Figure 8. The presence of capsulitis characterized by the presence of fibrin,
polymorphonuclear leukocytes, and lymphocytes on the peritoneal side of the spleen of
an animal treated with flurbiprofen, which also underwent cecal ligation and puncture
(hematoxylin and eosin, 200×).
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Figure 9. Hematoxylin and eosin (200×, on the left) or trichrome (200×, on the right)
staining showing the presence of pericentral fibrosis in the liver of an animal treated
with flurbiprofen, which also underwent cecal ligation and puncture.

two different models of shock in the present study were
efficient, consistent, and in line with our previous work
and other publications (25–27). LPS-induced respiratory
failure model is an effective model for testing COX
inhibitors (12), and CLP is the best model of septic shock
that represents the clinical situation. The validity of CLP
has also been supported by previous publications where
it was shown that the blockade of tumor necrosis factor
alpha failed to prevent death in this model (29). This was
also shown in human clinical trials.
None of the test drugs in this study produced a
beneficial effect on the overall survival rates, nor did they
alleviate the spleen or liver injury in these septic models,
although some degree of improvement/protection was
obtained in the NCX 4016-treated group. The data are
consistent within themselves since aspirin and NCX 4016
survival curves displayed the same trend in the LPS model.
The mortality rates in both models were at such a level that
we were able to detect a worsening trend with aspirin and
NCX 4016 in the LPS model and some benefit with NCX
4016 in CLP. Spleen weight was not measured in the LPS
model, since the majority of the animals were lost within
a few hours, a time period that was not enough for spleen
enlargement.
The drug doses and their administration route can
be questioned. Twice-daily injections of aspirin (2 × 15
mg/kg) and flurbiprofen (2 × 3 mg/kg) were sufficient to
saturate the tissues and, unquestionably, to systemically
inhibit the COX. The particular doses used in this study
were supported by the literature (30). Even when strong
survival endpoints were not statistically reached, test
drugs were absorbed, since NCX 4016 displayed some
limited benefit and flurbiprofen was able to produce
fibrosis, necrosis, and spleen enlargement. Since one of the
solutions in the mixture of the vehicle, polyethylene glycol
400, is incompatible with salicylic acid, the vehicle should
be questioned. We found that the vehicle selected interacts
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with the CLP procedure (Figure 2). Therefore, this could
have an influence on the results.
We think that our study is a valuable addition to the
common knowledge in the field of septic and endotoxic
shock. Although we reported mostly negative results with
aspirin and flurbiprofen on overall mortality, other groups
have previously reported positive results on endotoxic
and septic shock models with some of the test drugs (8,9).
The differences in the findings could be explained by the
different techniques, animal strains, and endpoints that
were used by us and by other investigators. In our model,
the endpoint measurements were obtained on day 7 in the
CLP model, whereas shorter protocols were used by the
other investigators (31).
In conclusion, this study indicates that the choice
of vehicle for test drugs could have an influence on the
measurements of overall activity. NCX 4016 showed some
potential beneficial effect on overall mortality in septic
shock, which needs to be further confirmed with another
vehicle. In the present study, aspirin and flurbiprofen
did not improve overall mortality at 1 week after the
induction of CLP. However, the effects of arachidonic acidcyclooxygenase pathway blockade in endotoxic and septic
shock have to be extensively investigated before discussing
the relevance of the molecules in the treatment of human
septic shock.
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